velpatasvir (GS-5816) / Gilead - LARVOL DELTA

Targeting chitinase-3-like protein-1 in pancolitis by a drug-repurposing approach. (PubMed, Biochem Pharmacol) - "In HT-29/B6 cells, velpatasvir attenuated selected CHI3L1-induced inflammatory gene responses without evidence of overt cytotoxicity at the concentrations used. In conclusion, the novelty of this project lies in identifying CHI3L1 as a potential inflammation-associated drug target and in supercomputer-based screening and validation of velpatasvir as a lead compound for modulating CHI3L1-associated inflammatory signaling in pancolitis."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Oncology • Ulcerative Colitis • CHI3L1 • CXCL1 • FERMT1 • MMP3 • PTGDS • S100A8 • TCL1A

Elevation of anticancer drug-induced cytotoxicity by velpatasvir through downregulation of claudin-14 expression in human colorectal cancer cells. (PubMed, Eur J Pharmacol) - "CLDN14 expression was not decreased by other NS5A inhibitors, including ledipasvir, pibrentasvir, and daclatasvir...Consequently, VEL promoted the intracellular accumulation of doxorubicin and significantly potentiated its cytotoxic effects. Moreover, VEL enhanced the antitumor efficacy of other chemotherapeutic agents, including oxaliplatin and SN-38, the active metabolite of irinotecan. These findings suggest that VEL enhances anticancer drug sensitivity in CRC cells through lysosome-dependent downregulation of CLDN14 protein and suppression of Nrf2-dependent oxidative stress responses."

Journal • Colorectal Cancer • Hepatitis C • Infectious Disease • Oncology • Solid Tumor • NFE2L2

Repurposing antiviral drugs targeting RNA viruses: A focus on the fusion protein of human metapneumovirus. (PubMed, North Clin Istanb) - "This study provides compelling in silico evidence that drug repurposing of clinically approved antiviral agents may accelerate the development of effective HMPV-specific therapies. By targeting the highly conserved and functionally critical HMPV F protein, the identified candidate compounds offer strong translational potential and justify prioritization for experimental validation and preclinical investigation. Collectively, these results contribute to filling a critical therapeutic gap and support drug repurposing as a viable and time-efficient strategy to address emerging and neglected viral respiratory infections."

Journal • Hepatitis C • Infectious Disease • Inflammation • Respiratory Diseases

REAL-WORLD PREDICTORS OF TREATMENT FAILURE AND NS5A RESISTANCE SELECTION IN GENOTYPE 3 HEPATITIS C: A MULTICENTER COHORT WITH LONGITUDINAL SEQUENCING AND IN-SILICO MODELLING (ISPOR 2026) - "In GT3 infection, DAA failure is driven by cirrhosis and prior NS5A exposure. National Programs should implement resistance testing at failure and use resistance-guided, higher-barrier retreatment rather than recycling prior regimens."

Clinical • Real-world • Real-world evidence • Fibrosis • Genetic Disorders • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Obesity

Treatment Adherence to Oral Direct-Acting Antiviral Agents in Hepatitis C Infection. (PubMed, Pharmacotherapy) - "Overall adherence to DAA therapy was high in HCV; however, several clinical and non-clinical factors were associated with non-adherence. Findings from this study can inform the development of targeted interventions to optimize DAA adherence in HCV."

Journal • Retrospective data • Fibrosis • Hepatitis C • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation

Repurposing antiviral agents against mucormycosis. (PubMed, PLoS One) - "Four candidates, IMB-301, U18666A, BLT-1, and obefazimod, showed potent in vitro effects, with three sustaining growth suppression comparable to AmB for up to 48 h in time-kill assays. The hepatitis C antivirals daclatasvir (DAC) and velpatasvir (VEL) demonstrated strong synergy with AmB across Mucorales isolates, lowering AmB MICs by 4- to 32-fold (ΣFICI 32 indicated favorable safety margins. These findings highlight antiviral repurposing as a promising strategy to expand treatment options for mucormycosis and support further translational development."

Journal • Hepatitis C • Infectious Disease • Inflammation

Integrative multiomics dissection of LSM7 as a prognostic biomarker and therapeutic target in hepatocellular carcinoma. (PubMed, Sci Prog) - "The high-LSM7 group showed increased sensitivity to drugs like sorafenib. Virtual screening identified Velpatasvir as a top LSM7-targeting candidate, with in vitro validation confirming that it inhibits MHCC97H cells and Huh-7 cells proliferation and downregulates LSM7 protein in a concentration- and time-dependent manner.ConclusionsBy integrating multiomics strategy and experimental validation, this study suggests that LSM7 may play a role in HCC progression and influence the tumor immune microenvironment. LSM7 may serve as a potential biomarker and therapeutic target, and Velpatasvir appears to be a candidate agent worthy of further investigation."

Biomarker • Journal • Hepatocellular Cancer • Oncology • Solid Tumor

Repurposing of FDA-Approved Antiviral Drugs Against Monkeypox Virus: Comparative In Vitro Screening and Structure Based In Silico Studies. (PubMed, Pharmaceuticals (Basel)) - "Twenty-three FDA-approved drugs, including Abacavir, Acyclovir, Amantadine, Chloroquine, Daclatasvir, Dolutegravir, Entecavir, Favipiravir, Hydroxychloroquine, Lamivudine, Molnupiravir, Nevirapine, Oseltamivir, Penciclovir, Remdesivir, Ribavirin, Sofosbuvir, Tenofovir, Valaciclovir, Valganciclovir, Velpatasvir, Zanamivir, and Zidovudine, were screened for potential anti-monkeypox activity in vitro...The employed computational methods indicate that remdesivir demonstrated superior binding patterns with elevated scores and stable complexes throughout the simulation. Our findings showed that Remdesivir therapeutic compound is potent against the tested strain of MPXV, and exhibited a robust binding affinity for Thymidylate Kinase, A42R Profilin-Like Protein, and VACV D13 enzymes, and thus may potentially be utilized as antiviral for the treatment of monkeypox virus."

FDA event • Journal • Preclinical • Infectious Disease

Deciphering virus host interaction analysis to unravel core virus network signatures and computational drug repurposing for cervical cancer. (PubMed, Comput Biol Med) - "Ten candidate drugs, Pleconaril, Pirodavir, Saquinavir, Delavirdine, and Tipranavir for VE7_HPV16 and Beclabuvir, Velpatasvir, Paritaprevir, Odalasvir, and Ledipasvir for VE6_HPV18, were predicted to exhibit high binding affinities with their respective viral targets. Additionally, Molecular Dynamics (MD) simulations were performed to examine the stability of the protein-ligand complexes and evaluate the role of SLiMs-containing regions in modulating virus-host interactions. Collectively, this comprehensive analysis of the virus-host network identified key HPV protein targets and proposed antiviral drug candidates to impede viral contributions to cervical carcinogenesis."

Journal • Cervical Cancer • Infectious Disease • Oncology • Solid Tumor

In silico screening of potential FGF2 inhibitors for cancer therapy. (PubMed, In Silico Pharmacol) - "Molecular docking study showed Elbasvir (1) to exhibit the strongest binding affinity (-8.1 kcal/mol), followed by Velpatasvir (2) (-7.6 kcal/mol), Daclatasvir (3) (-7.5 kcal/mol), Ritonavir (4) (-6.2 kcal/mol), Paliperidone Palmitate (5) (-5.9 kcal/mol), Saralasin (6) (-5.4 kcal/mol), Nystatin (8) (-5.2 kcal/mol), and Cobicistat (-5.1 kcal/mol)...Overall, the study provides mechanistic insights into the molecular interactions between FGF2 and these candidate drugs, highlighting the promising potential of compounds 1-6 and 8 for subsequent in vitro validation in cancer therapeutics. The online version contains supplementary material available at 10.1007/s40203-025-00495-2."

Journal • Acute Myelogenous Leukemia • Brain Cancer • Breast Cancer • Gastric Cancer • Glioblastoma • Hematological Malignancies • Leukemia • Lung Cancer • Nasopharyngeal Carcinoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • FGF2 • FGFR

Long-term changes in hepatic reserve and prognosis after direct-acting antiviral treatment in patients with hepatitis C virus-related decompensated cirrhosis: a five-year follow-up study of a Japanese phase 3 trial. (PubMed, J Gastroenterol) - "In HCV-related decompensated cirrhosis, 5 year LT-free survival rate after DAA was 74.7%, and viral clearance and post-treatment Child-Pugh class were associated with long-term prognosis. Child-Pugh class improved until 24 weeks after EOT, but little change was observed thereafter, which was closely associated with albumin levels."

Journal • P3 data • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation • Transplantation

LIVERRISK SCORE EFFECTIVELY PREDICTS FIBROSIS PROGRESSION AND MORTALITY IN HCV PATIENTS TREATED WITH DIRECT-ACTING ANTIVIRALS (UEGW 2025) - "A total of 26(38.2%) patients underwent upper endoscopy, among whom 13(19.11%) had esophageal varices, 2(2.9%) had gastric or gastroesophageal varices (GOV), and 9(13.2%) presented with hypertensive gastropathy.46(75.4%) were treated with Sofosbuvir and Daclatasvir, followed by Sofosvubir and Velpatasvir for 9(14.8%). The LiverRisk score is an accurate tool to predict liver fibrosis and mortality in HCV patients treated with direct acting antivirals."

Clinical • Addiction (Opioid and Alcohol) • Cardiovascular • Cholestasis • Diabetes • Fibrosis • Gastroenterology • Hematological Disorders • Hepatitis B • Hepatitis C • Hepatology • Hypertension • Immunology • Inflammation • Liver Cirrhosis • Metabolic Disorders • Portal Hypertension • Thrombocytopenia

OUTCOMES OF DIRECT ACTING ANTIVIRAL AGENTS IN CHRONIC HEPATITIS C PATIENTS WITH PRE-EXISTING HEPATOCELLULAR CARCINOMA (AASLD 2025) - "Patients were administered various DAAs; daclatasvir+asunaprevir, sofosvubir+ribavirin, sofosbuvir+daclatasvir, ledipasvir/Sofosbuvir±ribavirin, ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin, glecaprevir/pibrentasvir, velpatasvir/Sofobuvir ± ribavirin. This study demonstrated that the DAAs achieved favorable treatment outcomes and was well tolerated in CHC patients with pre-existing HCC. HCC tumor stage, presence of viable HCC and ribavirin use was significantly associated with survival."

Clinical • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Oncology • Solid Tumor

Assessment of direct-acting antiviral treatment outcomes in patients with chronic hepatitis C infected with various HCV genotypes: Insights from a real-world cohort in West Bengal, India. (PubMed, BMC Infect Dis) - "This study highlights genotype-specific variations in treatment response, with GT-3b exhibiting lower treatment response which highlights the need to decipher the reasons behind treatment failure for future therapeutic management."

Journal • Real-world evidence • Retrospective data • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Novel Coronavirus Disease

Hepatitis C Virus Cascade of Care After the Introduction of Direct-Acting Antiviral Medications in Suriname. (PubMed, Cureus) - "Although treatment with DAAs in Suriname is highly efficacious, several hurdles, including improving linkage and access to treatment, must be addressed to reduce the disease burden of HCV in Suriname successfully."

Journal • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation

Key population-led test and treat for hepatitis C virus infection in Thailand enables rapid initiation of treatment and achieved high virological success rates (IAS-HIV 2025) - "Those who met simplified treatment criteria (absence of advanced fibrosis score, hepatitis B (HBV) co-infection, or other medical concerns) received 12-week oral direct-acting antivirals (DAAs – sofosbuvir 400mg and velpatasvir 100mg once daily). KP-led HCV test-and-treat intervention enabled quick confirmation of active HCV-infection, quick DAAs initiation, and high rates of treatment completion and SVR. Clients referred out for treatment often did not initiate DAAs or did so after significant delays. To increase rates of SVR assessment, barriers for SVR testing should be explored to design and implement targeted interventions."

Clinical • Fibrosis • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Impact of Resistance Associated Substitutions and Predictors of Treatment Failure Following Direct-acting Antiviral Therapy in a Viral Hepatitis C Elimination Cohort. (PubMed, J Clin Exp Hepatol) - P=N/A | "The National Viral Hepatitis Control Program (NVHCP) has a cure rate of 91.6% when using direct-acting antivirals (DAAs)-sofosbuvir with an NS5A inhibitor (ledipasvir, daclatasvir or velpatasvir) ± ribavirin in the Punjab hub-and-spoke model of hepatitis C virus (HCV) elimination...Among these Y93K, L30R, G30 H/R confer resistance to velpatasvir; such patients received retreatment with voxilaprevir-containing regimens...RAS do not appear to be a primary factor for treatment failure in a public health setting. NCT03488485 available from https://clinicaltrials.gov/study/NCT03488485."

Journal • Fibrosis • Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation

Real-world outcomes in patients with Voxilaprevir (VOX)/Velpatasvir (VEL)/Sofosbuvir (SOF) treatment failure: a follow-up study (EASL 2025) - "Most of the patients had been pre-treated with VEL/SOF (55%, 17/31), 13% (4/31) each had received G/P (glecaprevir/pibrentasvir) or GZR/EBR(grazoprevir/elbasvir)±SOF and 10% (3/31) each had been pretreated with LDV(ledipasvir)/SOF or DCV(daclatasvir)/SOF. The combination of G/P+SOF represents an effective third-line treatment option for difficult-to-treat patients, including those with cirrhosis, HCC, or HCV GT3 infection. These findings highlight the importance of tailored salvage therapy to achieve optimal outcomes in this challenging population."

Clinical • Real-world • Real-world evidence • Fibrosis • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Oncology • Solid Tumor

Real-world outcomes in patients with Voxilaprevir (VOX)/Velpatasvir (VEL)/Sofosbuvir (SOF) treatment failure: a follow-up study (EASL 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Hepatitis C • Hepatology • Infectious Disease

The Genotypes/Subtypes and Antiviral Drug Resistance of the Hepatitis C Virus from Patients in a Tertiary Care Hospital in Nepal. (PubMed, Viruses) - "Resistant mutations against sofosbuvir, pibrentasvir, velpatasvir, daclatasvir, and dasabuvir were found at 25%, 18%, 16%, 16%, and 2%, respectively, mostly on subtype 3a. The predominant HCV genotype/subtype in our patient group was 3a, and resistance mutations against direct-acting antivirals were found in most untreated patients."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

High rates of active hepatitis C (HCV) infection and rapid treatment initiation: results from Thailand's first key population-led HCV test and treat intervention (APASL 2025) - "Those with active HCV infection received telehealth consultations with physicians from affiliated sites, and clients eligible for simplified treatment (absence of cirrhosis, hepatitis B co-infection, or other medical concerns) received 12 weeks of once-daily fixed dose combination of sofosbuvir (400mg) and velpatasvir (100mg). We observed high HCV infection rates among men who have sex with men and transgender women, as well as high rates of co-infections with HIV and other STIs. Onsite HCV-RNA testing facilitated the rapid identification of active HCV infection and all clients eligible for simplified treatment initiated direct acting antivirals within a week. Clients referred out for treatment were less likely to initiate treatment, or did so with significant delays."

Clinical • Fibrosis • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries. (PubMed, BMJ Open Gastroenterol) - "The high prevalence of HCV genotypes 1b and 3a in the FSU region and the presence of specific RASs should be considered when determining the most effective treatment regimen for HCV-infected individuals in the FSU countries."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16-24 weeks. (PubMed, J Virol) - "The outcomes of retreatment patients infected with hepatitis C virus genotype 3, cirrhosis, with velpatasvir may be affected by treatment failure with velpatasvir. The presence of NS5A resistance-associated substitution mutations, including Y93H, and the number and regimens of the past failed therapy do not influence the likelihood of achieving sustained virological response. When velpatasvir treatment fails, pibrentasvir should be used as the first choice for retreatment."

Journal • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation

Reinfection and resistance associated substitutions following a minimal monitoring approach for HCV treatment in MINMON trial. (PubMed, Clin Infect Dis) - "Accounting for reinfections, SVR in MINMON was 97.0% further supporting simplified HCV treatment. No significant difference in SVR was found by baseline velpatasvir RAS. The high reinfection rate, especially among MSM with HIV, underscores the need to scale-up evidence-based interventions to reduce reinfection."

Journal • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Real-World Experience, Effectiveness, and Safety of Direct-Acting Antivirals for the Treatment of Hepatitis C in Oman: A Cross-Sectional, Multicenter Study. (PubMed, J Clin Med) - " A cross-sectional study was conducted including 375 HCV patients with different genotypes, treated using different DAA regimens, with or without ribavirin, between January 2012 and December 2020 at the Sultan Qaboos University Hospital and the medical city for military and security services, two tertiary hospitals in Muscat, Oman...No significant adverse effects were reported. Based on our real-world experience, DAAs are highly effective in treating patients with HCV infection in Oman, with an excellent tolerability and safety profile."

Clinical • Journal • Real-world • Real-world evidence • Fibrosis • Gastroenterology • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Oncology • Solid Tumor